Century Therapeutics, Inc. IPSC
We take great care to ensure that the data presented and summarized in this overview for Century Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IPSC
View all-
Bain Capital Life Sciences Investors, LLC Boston, MA3.54MShares$1.66 Million0.57% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.36 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.59MShares$1.22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.1MShares$988,8180.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$800,9890.23% of portfolio
-
Casdin Capital, LLC New York, NY1.23MShares$577,2490.08% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X01.21MShares$570,1362.17% of portfolio
-
Two Sigma Investments, LP New York, NY911KShares$428,3790.0% of portfolio
-
Tang Capital Management LLC San Diego, CA900KShares$423,0000.02% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny858KShares$403,0720.0% of portfolio
Latest Institutional Activity in IPSC
Top Purchases
Top Sells
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions at IPSC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2025
|
Chad Cowan Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
58,060
+5.26%
|
$0
$0.85 P/Share
|
|
Dec 12
2025
|
Brent Pfeiffenberger President and CEO |
BUY
Open market or private purchase
|
Direct |
52,000
+1.54%
|
$0
$0.58 P/Share
|
|
Dec 10
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
463
-0.01%
|
$0
$0.53 P/Share
|
|
Dec 08
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
257
-0.06%
|
$0
$0.53 P/Share
|
|
Dec 08
2025
|
Gregory Russotti |
SELL
Open market or private sale
|
Direct |
526
-0.13%
|
$0
$0.53 P/Share
|
|
Nov 20
2025
|
Chad Cowan Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,462
-0.55%
|
$0
$0.5 P/Share
|
|
Nov 19
2025
|
Brent Pfeiffenberger President and CEO |
BUY
Open market or private purchase
|
Direct |
35,000
+1.06%
|
$0
$0.5 P/Share
|
|
Nov 17
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
32,456
-0.99%
|
$0
$0.45 P/Share
|
|
Nov 03
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
292
-0.07%
|
$0
$0.59 P/Share
|
|
Sep 18
2025
|
Chad Cowan Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
762,543
+43.45%
|
-
|
|
Sep 08
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
263
-0.06%
|
$0
$0.5 P/Share
|
|
Sep 08
2025
|
Gregory Russotti |
SELL
Open market or private sale
|
Direct |
539
-0.14%
|
$0
$0.5 P/Share
|
|
Sep 08
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
488
-0.01%
|
$0
$0.5 P/Share
|
|
Aug 14
2025
|
Brent Pfeiffenberger President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,587,614
+32.69%
|
-
|
|
Aug 04
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
296
-0.07%
|
$0
$0.53 P/Share
|
|
Jun 09
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
475
-0.03%
|
$0
$0.62 P/Share
|
|
Jun 09
2025
|
Adrienne Farid Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
552
-0.22%
|
$0
$0.62 P/Share
|
|
Jun 09
2025
|
Douglas Carr SVP Finance & Operations |
SELL
Open market or private sale
|
Direct |
4,904
-1.19%
|
$0
$0.62 P/Share
|
|
Jun 09
2025
|
Gregory Russotti |
SELL
Open market or private sale
|
Direct |
526
-0.13%
|
$0
$0.62 P/Share
|
|
May 16
2025
|
Brent Pfeiffenberger President and CEO |
SELL
Open market or private sale
|
Direct |
29,552
-1.73%
|
$0
$0.55 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.25M shares |
|---|---|
| Open market or private purchase | 145K shares |
| Open market or private sale | 122K shares |
|---|---|
| Payment of exercise price or tax liability | 463 shares |